Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269082 · ClinicalTrials.gov registry record
A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 72
- Enrollment target
NCT05269082 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 72 participants.
The verdict
NCT05269082 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
Study Summary
The aim of this study is to find out whether TAK-880 creates hypersensitivity reactions compared to Gammagard S/D by testing blood taken from participants who have a higher risk of becoming hypersensitive to immunoglobulin products. This study is about collecting data available in the participant's medical record. No study medicines will be provided to participants in this study. Each participant will fill out a study questionnaire during a routine doctor visit. Blood will be taken from participants who have a higher risk of developing hypersensitivity reactions to immunoglobulin products.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2022-09-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05269082
The ClinicalTrials.gov registry entry for NCT05269082 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT05269082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05269082 about?
NCT05269082 is a clinical study titled "A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults". The aim of this study is to find out whether TAK-880 creates hypersensitivity reactions compared to Gammagard S/D by testing blood taken from participants who have a higher risk of becoming hypersensitive to immunoglobulin products. This study is about collecting data available in the participant's...
What is the current status of trial NCT05269082?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2022-04-05. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT05269082?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT05269082?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.